Article ; Online: COVID-19 and IL-6: Why vitamin D (probably) helps but tocilizumab might not.
European journal of pharmacology
2021 Volume 899, Page(s) 174031
Abstract: Interleukin 6 (IL-6), which is involved in the cytokine storm phenomenon, is a therapeutic target in COVID-19, but monoclonal receptor antibody therapeutic agents such as tocilizumab have demonstrated mixed results. Could Vitamin D, which modulates IL-6, ...
Abstract | Interleukin 6 (IL-6), which is involved in the cytokine storm phenomenon, is a therapeutic target in COVID-19, but monoclonal receptor antibody therapeutic agents such as tocilizumab have demonstrated mixed results. Could Vitamin D, which modulates IL-6, be more effective than currently deployed IL-6 antagonists, including tocilizumab, thereby presenting a useful therapeutic option in COVID-19? A narrative review of published trials examining the effect of Vitamin D administration in COVID-19 patients was conducted, and the theoretical basis for the use of tocilizumab as an IL-6 antagonist was compared with the immunomodulatory effect of Vitamin D on IL-6 production. Four of the six included studies reported a positive effect of Vitamin D on outcomes. While tocilizumab non-selectively blocks both anti-inflammatory and pro-inflammatory actions of IL-6, Vitamin D lowers immune cell IL-6 production, potentially reducing pro-inflammatory effects, but does not specifically target IL-6 receptors, avoiding any deleterious effect on the anti-inflammatory actions of IL-6. Vitamin D may have advantages over tocilizumab as an IL-6 immunomodulator, and, given that it is safe if administered under clinical supervision, there is a strong rationale for its use. |
---|---|
MeSH term(s) | Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19/drug therapy ; Cytokine Release Syndrome/etiology ; Cytokine Release Syndrome/therapy ; Humans ; Interleukin-6/antagonists & inhibitors ; Interleukin-6/blood ; Vitamin D/therapeutic use ; Vitamins/therapeutic use |
Chemical Substances | Antibodies, Monoclonal, Humanized ; IL6 protein, human ; Interleukin-6 ; Vitamins ; Vitamin D (1406-16-2) ; tocilizumab (I031V2H011) |
Language | English |
Publishing date | 2021-03-13 |
Publishing country | Netherlands |
Document type | Journal Article ; Review |
ZDB-ID | 80121-5 |
ISSN | 1879-0712 ; 0014-2999 |
ISSN (online) | 1879-0712 |
ISSN | 0014-2999 |
DOI | 10.1016/j.ejphar.2021.174031 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 522: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.